KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS-Reference-Cited by-同舟云学术

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Published:2018-02 Issue:4 Volume:172 Page:857-868.e15
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Ambrogio Chiara,Köhler Jens,Zhou Zhi-Wei,Wang Haiyun,Paranal Raymond,Li Jiaqi,Capelletti Marzia,Caffarra Cristina,Li Shuai,Lv Qi,Gondi Sudershan,Hunter John C.,Lu Jia,Chiarle Roberto,Santamaría David,Westover Kenneth D.,Jänne Pasi A.

Funder

American Cancer Society

Gadzooks Fund

Cammarata Family Foundation Research Fund

US Department of Defense

Cancer Prevention and Research Institute of Texas

National Natural Science Foundation of China

German Cancer Aid Foundation

American Association for Cancer Research

AstraZeneca

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference46 articles.

1. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals;Albeck;Mol. Cell,2013

2. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts;Ambrogio;Cancer Res.,2014

3. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma;Ambrogio;Nat. Med.,2016

4. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†;Blumenschein;Ann. Oncol.,2015

5. Clinically viable gene expression assays with potential for predicting benefit from MEK inhibitors;Brant;Clin. Cancer Res.,2017

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade;Nature Communications;2024-08-30

2. Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody;Scientific Reports;2024-08-23

3. Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors;Oncogene;2024-08-16

4. Capturing RAS oligomerization on a membrane;Proceedings of the National Academy of Sciences;2024-08-15

5. Effector Binding Sequentially Alters KRAS Dimerization on the Membrane: New Insights Into RAS‐Mediated RAF Activation;Advanced Science;2024-08-13